Past, present and future of therapies in pediatric sarcomas

Area of Science:

• Pediatric Oncology
• Cancer Therapeutics
• Molecular Biology

Background:

• High-risk pediatric sarcomas have shown dismal 5-year survival rates, not exceeding 20% for metastatic cases.
• Limited therapeutic advancements over the last 30 years necessitate novel treatment strategies.

Purpose of the Study:

• To review the current landscape of novel therapeutic agents and immunotherapies for high-risk pediatric sarcomas.
• To discuss the successes, failures, and future directions of these investigational treatments.

Main Methods:

• Review of recent research and clinical trials focusing on targeted molecular agents and immunotherapies.
• Analysis of promising drug classes including IGF-1 receptor antibodies, mTOR inhibitors, oncolytic viruses, epigenetic modulators, and immune modulators.
• Examination of emerging immunotherapies such as dendritic cell vaccines and adoptive immunotherapy.

Main Results:

• IGF-1 receptor antibodies and mTOR inhibitors demonstrate significant potential in preclinical and early clinical studies.
• Other agents like oncolytic viruses and epigenetic modulators are under investigation for their efficacy.
• Immunotherapies, including dendritic cell vaccines and adoptive T-cell therapy, represent a growing area of research.

Conclusions:

• Targeted molecular therapies and novel immunotherapies offer new hope for improving outcomes in pediatric sarcomas.
• Continued research into drug combinations and personalized treatment approaches is crucial.
• Addressing the challenges and failures is essential for advancing the clinical application of these innovative therapies.